Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Radiology and Oncology
Volume 56 (2022): Issue 4 (December 2022)
Open Access
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
Anze Smole
Anze Smole
| Dec 13, 2022
Radiology and Oncology
Volume 56 (2022): Issue 4 (December 2022)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
review
Published Online:
Dec 13, 2022
Page range:
409 - 419
Received:
Oct 19, 2022
Accepted:
Oct 27, 2022
DOI:
https://doi.org/10.2478/raon-2022-0049
© 2022 Anze Smole, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor
Figure 2
Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment
Figure 3
Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.